LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: How to Test Human CAR T Cells in Solid Tumors, the Next Frontier of CAR T Cell Therapy.

    Cochrane, Russell W / Fiorentino, Andrew / Allen, Eva / Robino, Rob A / Quiroga, Jaime / Ferreira, Leonardo M R

    Methods in molecular biology (Clifton, N.J.)

    2023  Volume 2748, Page(s) 243–265

    Abstract: Chimeric antigen receptor (CAR) T cell therapy has proven to be a successful treatment option for leukemias and lymphomas. These encouraging outcomes underscore the potential of adoptive cell therapy for other oncology applications, namely, solid tumors. ...

    Abstract Chimeric antigen receptor (CAR) T cell therapy has proven to be a successful treatment option for leukemias and lymphomas. These encouraging outcomes underscore the potential of adoptive cell therapy for other oncology applications, namely, solid tumors. However, CAR T cells are yet to succeed in treating solid tumors. Unlike liquid tumors, solid tumors create a hostile tumor microenvironment (TME). CAR T cells must traffic to the TME, survive, and retain their function to eradicate the tumor. Nevertheless, there is no universal preclinical model to systematically test candidate CARs and CAR targets for their capacity to infiltrate and eliminate human solid tumors in vivo. Here, we provide a detailed protocol to evaluate human CAR CD4
    MeSH term(s) Humans ; Animals ; Mice ; Immunotherapy, Adoptive/methods ; Receptors, Chimeric Antigen/genetics ; Neoplasms/pathology ; T-Lymphocytes ; Tumor Microenvironment
    Chemical Substances Receptors, Chimeric Antigen
    Language English
    Publishing date 2023-12-09
    Publishing country United States
    Document type Journal Article
    ISSN 1940-6029
    ISSN (online) 1940-6029
    DOI 10.1007/978-1-0716-3593-3_16
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Redirecting Human Conventional and Regulatory T Cells Using Chimeric Antigen Receptors.

    Zimmerman, Capers M / Robino, Rob A / Cochrane, Russell W / Dominguez, Matthew D / Ferreira, Leonardo M R

    Methods in molecular biology (Clifton, N.J.)

    2023  Volume 2748, Page(s) 201–241

    Abstract: The adaptive immune system exhibits exquisite specificity and memory and is involved in virtually every process in the human body. Redirecting adaptive immune cells, in particular T cells, to desired targets has the potential to lead to the creation of ... ...

    Abstract The adaptive immune system exhibits exquisite specificity and memory and is involved in virtually every process in the human body. Redirecting adaptive immune cells, in particular T cells, to desired targets has the potential to lead to the creation of powerful cell-based therapies for a wide range of maladies. While conventional effector T cells (Teff) would be targeted towards cells to be eliminated, such as cancer cells, immunosuppressive regulatory T cells (Treg) would be directed towards tissues to be protected, such as transplanted organs. Chimeric antigen receptors (CARs) are designer molecules comprising an extracellular recognition domain and an intracellular signaling domain that drives full T cell activation directly downstream of target binding. Here, we describe procedures to generate and evaluate human CAR CD4
    MeSH term(s) Humans ; Receptors, Chimeric Antigen/metabolism ; T-Lymphocytes, Regulatory ; Receptors, Antigen, T-Cell/genetics ; Receptors, Antigen, T-Cell/metabolism
    Chemical Substances Receptors, Chimeric Antigen ; Receptors, Antigen, T-Cell
    Language English
    Publishing date 2023-12-09
    Publishing country United States
    Document type Journal Article
    ISSN 1940-6029
    ISSN (online) 1940-6029
    DOI 10.1007/978-1-0716-3593-3_15
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: High affinity chimeric antigen receptor signaling induces an inflammatory program in human regulatory T cells.

    Cochrane, Russell W / Robino, Rob A / Granger, Bryan / Allen, Eva / Vaena, Silvia / Romeo, Martin J / de Cubas, Aguirre A / Berto, Stefano / Ferreira, Leonardo M R

    bioRxiv : the preprint server for biology

    2024  

    Abstract: Regulatory T cells (Tregs) are promising cellular therapies to induce immune tolerance in organ transplantation and autoimmune disease. The success of chimeric antigen receptor (CAR) T-cell therapy for cancer has sparked interest in using CARs to ... ...

    Abstract Regulatory T cells (Tregs) are promising cellular therapies to induce immune tolerance in organ transplantation and autoimmune disease. The success of chimeric antigen receptor (CAR) T-cell therapy for cancer has sparked interest in using CARs to generate antigen-specific Tregs. Here, we compared CAR with endogenous T cell receptor (TCR)/CD28 activation in human Tregs. Strikingly, CAR Tregs displayed increased cytotoxicity and diminished suppression of antigen-presenting cells and effector T (Teff) cells compared with TCR/CD28 activated Tregs. RNA sequencing revealed that CAR Tregs activate Teff cell gene programs. Indeed, CAR Tregs secreted high levels of inflammatory cytokines, with a subset of FOXP3
    Language English
    Publishing date 2024-04-01
    Publishing country United States
    Document type Preprint
    DOI 10.1101/2024.03.31.587467
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top